Next Article in Journal
Special Issue: Candida and Candidiasis
Next Article in Special Issue
Present and Future Therapy of Cryptococcus Infections
Previous Article in Journal
Vitamin Biosynthesis as an Antifungal Target

Recent Advances in the Treatment of Scedosporiosis and Fusariosis

Division of General Internal Medicine, Weill Cornell Medicine of Cornell University, New York, NY 10065, USA
Department of Pediatrics, Division of Pediatric Infectious Diseases, Nationwide Children’s Hospital and The Ohio State University, Columbus, OH 43205, USA
Infectious Diseases Section, 3rd Department of Pediatrics, Faculty of Medicine, Aristotle University School of Health Sciences, 54642 Thessaloniki, Greece
Transplantation-Oncology Infectious Diseases Program, Departments of Pediatrics, and Microbiology & Immunology, Weill Cornell Medicine, New York, NY 10065, USA
Author to whom correspondence should be addressed.
These authors contributed equally to this manuscript.
J. Fungi 2018, 4(2), 73;
Received: 26 April 2018 / Revised: 13 June 2018 / Accepted: 16 June 2018 / Published: 18 June 2018
(This article belongs to the Special Issue Treatments for Fungal Infections)
Species of Scedosporium and Fusarium are considered emerging opportunistic pathogens, causing invasive fungal diseases in humans that are known as scedosporiosis and fusariosis, respectively. These mold infections typically affect patients with immune impairment; however, cases have been reported in otherwise healthy individuals. Clinical manifestations vary considerably, ranging from isolated superficial infection to deep-seated invasive infection—affecting multiple organs—which is often lethal. While there have been a number of advances in the detection of these infections, including the use of polymerase chain reaction (PCR) and matrix-assisted laser desorption ionization/time-of-flight mass spectrometry (MALDI-TOF MS), diagnosis is often delayed, leading to substantial morbidity and mortality. Although the optimal therapy is controversial, there have also been notable advances in the treatment of these diseases, which often depend on a combination of antifungal therapy, reversal of immunosuppression, and in some cases, surgical resection. In this paper, we review these advances and examine how the management of scedosporiosis and fusariosis may change in the near future. View Full-Text
Keywords: fusariosis; scedosporiosis; isavuconazole; voriconazole; MALDI-TOF fusariosis; scedosporiosis; isavuconazole; voriconazole; MALDI-TOF
MDPI and ACS Style

McCarthy, M.W.; Katragkou, A.; Iosifidis, E.; Roilides, E.; Walsh, T.J. Recent Advances in the Treatment of Scedosporiosis and Fusariosis. J. Fungi 2018, 4, 73.

AMA Style

McCarthy MW, Katragkou A, Iosifidis E, Roilides E, Walsh TJ. Recent Advances in the Treatment of Scedosporiosis and Fusariosis. Journal of Fungi. 2018; 4(2):73.

Chicago/Turabian Style

McCarthy, Matthew W., Aspasia Katragkou, Elias Iosifidis, Emmanuel Roilides, and Thomas J. Walsh. 2018. "Recent Advances in the Treatment of Scedosporiosis and Fusariosis" Journal of Fungi 4, no. 2: 73.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop